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Abstract
Background and Objective: Blood vessel invasion plays a very important role in the progression and metastasis of cancer.
However, blood vessel invasion as a prognostic factor for survival in non-small cell lung cancer (NSCLC) remains
controversial. The aim of this study is to explore the relationship between blood vessel invasion and outcome in patients
with NSCLC using meta-analysis.
Methods: A meta-analysis of published studies was conducted to investigate the effects of blood vessel invasion on both
relapse-free survival (RFS) and overall survival (OS) for patients with NSCLC. Hazard ratios (HRs) with 95% confidence
intervals (95% CIs) were used to assess the strength of this association.
Results: A total of 16,535 patients from 52 eligible studies were included in the systematic review and meta-analysis. In total,
blood vessel invasion was detected in 29.8% (median; range from 6.2% to 77.0%) of patients with NSCLC. The univariate and
multivariate estimates for RFS were 3.28 (95% CI: 2.14–5.05; P,0.0001) and 3.98 (95% CI: 2.24–7.06; P,0.0001), respectively.
For the analyses of blood vessel invasion and OS, the pooled HR estimate was 2.22 (95% CI: 1.93–2.56; P,0.0001) by
univariate analysis and 1.90 (95% CI: 1.65–2.19; P,0.0001) by multivariate analysis. Furthermore, in stage I NSCLC patients,
the meta-risk for recurrence (HR=6.93, 95% CI: 4.23–11.37, P,0.0001) and death (HR=2.15, 95% CI: 1.68–2.75; P,0.0001)
remained highly significant by multivariate analysis.
Conclusions: This study shows that blood vessel invasion appears to be an independent negative prognosticator in
surgically managed NSCLC. However, adequately designed large prospective studies and investigations are warranted to
confirm the present findings.
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Introduction
Non-small cell lung cancer (NSCLC) constitutes approximately
80% of all cases of primary lung cancers and is one of the most
common tumors worldwide [1]. Although surgical resection is the
current standard of treatment for early-stage patients, only 15% of
patients diagnosed with NSCLC survive for 5 years [2]. Prognostic
factors may identify subsets of patients with a worse prognosis and
facilitate the selection of a more aggressive treatment strategy. The
tumor-node-metastasis (TNM) staging system is the best prognos-
tic index for operable NSCLC [2]. However, each patient’s
prognosis varies significantly within each TNM stage, which
makes it difficult to predict accurately the outcome for each
patient, especially for patients with early-stage lung cancer.
The degree of histological differentiation, extent of operation,
visceral pleural invasion, and many biological factors involving in
cancer development and progression are useful for predicting
survival and aiding the management of patients with NSCLC [3–
5]. Our previous meta-analysis concluded that the methylation of
RASSF1A within its promoter region could serve as an independent
prognostic marker for NSCLC [6]. In the latest edition (7th) of the
TNM classification, tumor size is evaluated in detail, with visceral
pleural invasion clearly defined; T1 tumors are still classified as T2
if the visceral pleura elastic layer is invaded [1]. In testicular germ
cell tumors, cancer cell invasion of blood vessels qualifies as a local
spread of tumors. Testicular tumors localized to the testis and
epididymis are classified as T1 when blood vessel invasion (BVI) is
absent, whereas they are upgraded to T2 if vascular invasion is
present [7].
In 1992, Macchiarini et al. first demonstrated that NSCLC
patients harboring BVI have a significant tendency to relapse in
the first 5-year period after surgery and would be suitable for
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reported to be a strong predictor of recurrence [9–19] or death for
patients with NSCLC in many studies [8–10,12,16,17,20–47], but
has not been confirmed in other studies [48–55]. Based on the
discordant results obtained by a large number of studies on lung
cancer, we performed a literature-based systematic review to
better quantify the prognostic effects of BVI on both relapse-free
survival (RFS) and overall survival (OS) in patients with NSCLC.
Materials and Methods
Publication selection, data extraction and
methodological assessment
Studies were identified via a search of the electronic databases
PubMed (National Library of Medicine, Bethesda, USA) and
EMBASE (Elsevier, Amsterdam, the Netherlands) between 1980
and 2011 using the following key words: non-small cell lung
cancer, NSCLC, vessel invasion, vascular invasion, relapse,
recurrence, prognostic and prognosis (last search was updated on
July 10, 2011). To be eligible for inclusion, studies had to meet the
following criteria: (i) blood vessel invasion (not lymphovascular
invasion) was measured in surgically resected primary tumor
samples, and (ii) the relationship between BVI and survival was
investigated, and the results were published as a full paper.
Abstracts, reviews and case reports were excluded because of
insufficient data for meta-analysis. Non-English language papers
were not included in the review. To avoid duplication of patient
data, we carefully noted the author names and the research centers
involved for all authors. If more than one publication reported the
same population data, only the most recently reported data or
complete data were used. We also performed a manual search
from the references of relevant publications, including original
articles and reviews, to identify additional studies. Three authors
(J. Wang, J. Chen and X. Chen) did the search and identification
independently using a standardized approach, and the selection of
a study was reached by consensus. Information retrieved from the
reports included author names, year of publication, patient
resources, study size, methods, histology, and disease stage.
Methodological assessment was also independently performed by
three investigators (J. Wang, J. Chen and X. Chen). Disagreements
were adjudicated by a third investigator (B. Wang) after referring
to the original articles. Scoring for each study was conducted
according to the European Lung Cancer Working Party scale by
Steels et al [3]. Studies included in the systematic review were
denoted ‘eligible’, and those providing sufficient data for the meta-
analysis are denoted ‘evaluable’.
Statistical methods
We performed separate meta-analyses using an adjusted or
unadjusted hazard ratio (HR) for RFS and OS. Usually, HRs and
95% confidence intervals (CIs) were directly obtained from published
literatures using univariate [8–11,13–15,18,19] or multivariate
survival analyses. In some studies, BVI was determined to be an
independent prognostic indicator using multivariate analysis; HRs
and 95% CIs were generally reported [9,10,16,18,20,21,23,26–
29,31,33–36,38,40–45,47–49,52,56–59,60]. Some studies reported
the HR but did provide sufficient information on survival by BVI
status; we thus estimated the HRand CIs according to the methods of
Parmar et al [61]. As shown in Table S1, the total number of events
[53], the log-rank statistic or its P value [9–12,14,17,18,20–
22,25,27,28,34,35,39–42,44,46,47,50,51,54,57,58], or data from
Kaplan-Meier survival curves [16–19,59] were used to allow an
approximate calculation of the HR. Heterogeneity was tested with
the x
2-based Q test [62]. When the effects were assumed to be
homogenous, thefixed-effect modelwasused; otherwise, therandom-
effect model based on Mantel–Haenszel method was applied [36] A
funnel plot and Egger’s linear regression test were used to investigate
any possible publication bias [63]. The correlation between the score
measurements was determined using the Spearman rank correlation
coefficient. The score measurements involving the value of a discrete
variable were calculated using the nonparametric Mann-Whitney U
test. For all analyses, a two-sided P value of ,0.05 was considered
statistically significant. All analyses were performed using STATA
version 11.0software (Stata Corporation, College Station, TX, USA).
Results
Study selection and characteristics
In total, our electronic data search retrieved 206 references.
Four studies were excluded because an identical patient cohort
occurred within another selected cohort [64–67]. Eight studies
were not included in the overall meta-analysis because they
investigated lymphovascular invasion and outcome in NSCLC
patients. The other excluded records include 19 reviews, 3 other
diseases, 3 case reports, 13 non-English articles and 103 studies
without available survival information (Table S2). Macchiarini et
al. analyzed the correlation between BVI and outcome in 28
patients receiving induction therapy [68]. This study was also
excluded from the systematic review because it did not meet the
inclusion criteria. Finally, there were 52 eligible studies investi-
gating the prognostic value of BVI in patients with NSCLC
published from 1993 to 2011. The PRISMA Checklist and Flow
Diagram for the studies is shown in Checklist S1 and Figure S1.
The individual characteristics of the 52 eligible studies are
reported in Table S3. The total number of patients was 16,535
(range, 35–2295; median, 171). In all, according to the positivity
for BVI as defined by the authors, 29.8% of tumors harbored BVI
by cancer cells (median; range from 6.2% to 77.0%). A total of 47
studies dealt with all types of NSCLC, four with adenocarcinoma
alone [14,27,38,41] and one with squamous cell carcinoma alone
[39]. A total of 23 studies dealt with only stage I patients. Twenty-
eight studies investigated blood vascular invasion by using
hematoxylin and eosin (H&E) stain alone. Three studies
investigated blood vascular invasion by staining with H&E and
for CD34 with or without CD31 immunochemistry [12,50,53].
Twenty studies evaluated the status of BVI in tumors in
combination with elastic staining.
Of the 52 publications eligible for systematic review, four were
not evaluable by meta-analysis owing to the lack of survival data
even after writing to the authors for complementary information
[30,32,53,55]. Twelve of the these eligible studies identified BVI as
a poor prognostic factor for RFS [8,10–14,16,18,19,21,60,69], and
three identified BVI as not significant for RFS [35,53,54] by
univariate analysis. However, three studies were not included in
final meta-analysis due to insufficient survival information [17,53]
or overlap between cohorts [10,11]. Eight studies reported the
significant prognostic role of BVI for RFS by multivariate analysis
[8,9–11,13–15,19,60], and two identified BVI as not significant for
RFS [18,54].
In univariate analysis, 33 studies identified blood vessels as a
significant prognostic factor for OS [8,9,12,20–25,27–34,43–
47,58,16,17,35,37–42,59], and seven identified it as not significant
for survival [18,50,52–55,70]. In multivariate analyses, there were
27 studies that identified BVI as a significant prognostic factor
for OS [8–10,16,20,23,26,27,31–47,58,59] and 10 that
identified blood vessel as a non-significant prognostic factor
[18,21,28,30,48,49,52,53,56,70]. Evaluability was not associated
with positivity in the systematic review. The rate of significant
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with 60.0% (2/4) for non-evaluable trials (P=0.626) irrespective of
whether these studies used univariate or multivariate analyses.
Quality assessment of study
As shown in Table 1, the global quality assessment score,
expressed as a percentage, ranged from 46.5% to 63.6%. There
was no significant association between the global score and the
number of patients in all eligible studies (P=0.32). As for the
global score, no significant difference was found between the
evaluable and the non-evaluable trials (P=0.18). Similarly, no
statistically significant difference was shown between the signifi-
cant trials and the non-significant trials in univariate (P=0.86) or
multivariate analysis for OS (P=0.52) (Table 1).
Meta-analysis of the impact of BVI on survival for all
patients
The results of meta-analysis of BVI and prognosis in NSCLC
are shown in Table 2. BVI was significantly correlated with poor
RFS according to univariate analysis, with a combined HR of 3.28
(95% CI: 2.14–5.05; P,0.0001) (11 studies, 4,498 patients).
Significant heterogeneity was detected among these studies
(P,0.001, Q=90.00). The data of multivariate analyses for RFS
were available in six studies including 3,088 patients. We obtained
a combined HR value of 3.98 (95% CI: 2.24–7.06; P,0.0001)
with significant heterogeneity (P,0.001, Q=34.44) (Fig. 1).
Thirty-one studies (comprising 8,528 cases) used for univariate
analysis produced a pooled estimate of risk of 2.22 (95% CI: 1.93–2.56,
P,0.0001). There was evidence of significant inter-study heterogeneity
(P,0.001, Q=79.63). Twenty-eight studies (comprising 9,873 cases)
were used for the meta-analysis of BVI on OS by multivariate analysis
(Fig. 2). The overall risk of death was 1.90 (95% CI: 1.65–2.19;
P,0.0001) with a range of estimates from 0.80 to 3.79. Significant
heterogeneity among studies was present (P,0.001, Q=84.40).
Meta-analysis of the impact of BVI on survival for stage I
patients
We also analyzed the association between the BVI and
survival in early-stage cancer patients. As shown in Table 2, the
summary HR estimates for stage I patients by univariate and
multivariate analysis were 2.94 (95% CI: 2.28–3.80; P,0.0001)
and 2.15 (95% CI: 1.68–2.75; P,0.0001) , respectively. BVI
demonstrated a significant effect on RFS for stage I NSCLC
according to univariate analysis (HR=5.89, 95% CI: 3.98–8.71,
P,0.0001) and multivariate analysis (HR=6.93, 95% CI: 4.23–
11.37, P,0.0001) (Fig. 3). These results suggest that NSCLC
patients with BVI have a poor prognosis, irrespective of the
tumor stage.
Test of heterogeneity and subgroup analyses
There was large heterogeneity in this meta-analysis. Firstly, we
performed the subgroup analyses stratified by ethnicity. BVI status
did show a significant effect on RFS according to multivariate
analysis in Asians (HR=3.87, 95% CI: 2.07–7.22, P,0.001;
heterogeneity test, P=0.006) and in Caucasians (HR=4.25, 95%
CI: 0.61–29.5, P,0.001; heterogeneity test, P=0.28). There was
still evidence of statistical heterogeneity in Asians that was largely
due to the contribution of the report by Maeda et al. which
included the largest patient population. Furthermore, the
heterogeneity disappeared when excluding this study and the
value of pooled HR was not significantly altered (HR=4.82, 95%
CI: 3.12–7.46, P,0.001; heterogeneity test, P=0.65). Subgroup
analyses by methods of BVI evaluation showed that the pooled
HRs for RFS by multivariate analysis were 4.91 (95% CI: 1.82–
13.24, P,0.001; heterogeneity test, P=0.06) in studies evaluating
BVI with H&E method and 3.16 (95% CI: 1.51–6.63, P,0.001;
heterogeneity test, P=0.02) in those evaluating BVI by a
combination of H&E method and immunochemistry or elastic
staining.
Table 1. Quality scores analysis of the 52 eligible studies by the European Lung Cancer Working Party score according to studies
characteristics.
Studies Design (/10)
Laboratory
method (/10)
Generalizability
(/10)
Results
analysis
Global score
(%)
All (52) 4.0 5.6 6.4 6.0 55.0
Patients number
Spearman r 0.17 0.14 0.10 0.25 0.14
P 0.22 0.32 0.47 0.08 0.32
Evaluable for meta-analysis
Yes (48) 4.0 4.2 6.4 7.5 58.9
No (4) 4.0 5.6 6.4 5.0 52.5
P 0.38 0.15 0.13 0 .36 0.18
Significant results for OS in univariate analysis
Yes (33) 4.0 4.9 5.6 7.5 59.5
No (7) 6.0 4.2 6.4 7.5 60.2
P 0.78 085 0.98 0.81 0.86
Significant results for OS in multivariate analysis
Yes (27) 4.0 5.6 6.4 7.0 55.3
No (10) 4.0 5.6 6.4 6.3 53.6
P 0.36 0.91 0.91 0.63 0.52
Scores distributions are summarized by median values.
OS=overall survival.
doi:10.1371/journal.pone.0028844.t001
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analysis.
doi:10.1371/journal.pone.0028844.g001
Figure 2. Forest plot showing the combined relative hazard ratio for overall survival in all patient populations by multivariate
analysis.
doi:10.1371/journal.pone.0028844.g002
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increased risks for death were found among Asians (HR=1.68,
95% CI: 1.53–1.85, P,0.001; heterogeneity test, P=0.06) and
among Caucasians (HR=1.74, 95% CI: 1.46–2.09, P,0.001;
heterogeneity test, P=0.45). In addition, BVI was significantly
correlated with poor OS according to multivariate analysis in
studies evaluating BVI with H&E method (HR=2.04, 95% CI:
1.68–2.47, P,0.001; heterogeneity test, P=0.03) and in those
evaluating BVI by a combination of H&E method and
immunochemistry or elastic staining (HR=1.60, 95% CI: 1.39–
1.84, P,0.001; heterogeneity test, P=0.28). These results showed
that the heterogeneities were effectively decreased or removed in
the subgroups by ethnicity and methods for BVI evaluation.
Publication bias statistics were determined using the methods of
Egger et al [63]. No publication bias was found for the studies used
for univariate analysis (P=0.596) or for multivariate analysis
(P=0.24).
Discussion
Microscopic metastasis begins with the local invasion by tumor
cells into host stroma within or surrounding the primary tumor.
When tumor cells penetrate a blood vessel or a peripheral
lymphatic, they can detach, disseminate and arrest in the
microvasculature through the circulation [70]. In fact, the
presence of vascular invasion by neoplastic cells indicates that
the cancers are in a metastatic phase. BVI was found to correlate
with disease progress in many types of cancers [71–73]. Our meta-
analysis provides strong evidence that pathologic BVI is a
prognostic factor for survival in patients with NSCLC by
univariate analysis. More importantly, this effect remained
significant according to multivariate analysis, showing that BVI
is an independent prognostic factor for poor survival regardless of
tumor size or lymph node status. In addition, vascular invasion is a
strong predictor of survival in early stage tumors when adjusted for
other prognostic factors.
Cancer metastasis and progression is a complex and multistep
process. BVI appears to be a fundamental step in cancer metastasis
and spread, leading to unfavorable prognosis for patients with
NSCLC. In general, BVI was defined as tumor cell embolization
in the vascular lumen on routine H&E and elastic lamina stain.
Ichinose et al. reported that venous invasion correlated with poor
prognosis among patients with completely resected NSCLC but
that arterial invasion did not [47]. However, in most of the studies,
arterial and venous invasion has not been separately studied
pathologically due to the inability in some cases to discriminate
between arterial and venous invasion. In addition, most of the
studies included in this meta-analysis investigated the correlation
between intratumoral BVI and prognosis, but some studies
demonstrated the prognostic role of extratumoral vascular
invasion. Shimada et al. reported that both intratumoral and
extratumoral vascular invasion were significant prognostic factors,
but only the extratumoral vascular invasion group was associated
with advanced pathologic staging, lymph node metastasis, and
lymphatic permeation [21]. Our meta-analysis focused on the
effect of tumor vascular invasion on the survival of NSCLC
patients irrespective of whether these studies detected intratumoral
or extratumoral vascular invasion or whether they determined
arterial and venous invasion. Although almost all intratumoral
blood vessels are occluded by the surrounding tumor cells and
stromal cells, intratumoral and extratumoral blood vessels are
thought to be functional blood vessels. In fact, Shimada et al.,
found that all extratumoral vascular invasion cases also had
intratumoral vascular invasion [21].
Our meta-analysis had some limitations. First, the level of
evidence obtained by retrospective studies is lower than that
provided by randomized controlled trials. Second, data from
published trials rather than individual patient data were used in
the systematic review. Third, in most of meta-analyses, there was
evidence of significant heterogeneity although the random-effect
model based on Mantel–Haenszel method rather than the fixed-
effect model was applied. Studies may have differed with regard to
the baseline characteristics of the patients included, the adjuvant
treatment they might have received, the duration of follow-up, and
adjustments for other cofactors. For example, some studies
included a small number of stage IV or IIIB patients, which
accounted for the heterogeneity. These studies were finally
maintained in the meta-analyses because the overall designs of
studies were similar to those used in the other studies. Many
variations to the method of BVI assessment exist, although in most
studies BVI was defined as the presence of neoplastic structures
inside the lumen of a vessel. Some studies detected BVI by staining
with hematoxylin and eosin alone or in combination with elastic-
van Gieson stain or by staining with Victoria blue hematoxylin
Table 2. Results of meta-analysis of blood vessel invasion and prognosis in NSCLC.
Groups Estimate of relative hazard Homogeneity test
HR 95% CI pQ (df) p
All studies
Unadjusted OS (31 studies, n=8,528) 2.22 1.93–2.56 ,0.0001 79.63 (33) ,0.001
Adjusted OS (28 studies, n=9,873) 1.90 1.65–2.19 ,0.0001 84.40 (28) ,0.001
Unadjusted RFS (11 studies, n=4,498 ) 3.28 2.14–5.05 ,0.0001 90.00 (10) ,0.001
Adjusted RFS (7 studies, n=3,088) 3.98 2.24–7.06 ,0.0001 34.44 (6) ,0.001
Stage I studies
Unadjusted OS (14 studies, n=2,908 ) 2.94 2.28–3.80 ,0.0001 22.83 (13) 0.044
Adjusted OS (13 studies, n=3,974) 2.15 1.68–2.75 ,0.0001 26.70 (12) 0.009
Unadjusted RFS (5 studies, n=647) 5.89 3.98–8.71 ,0.0001 3.76 (4) 0.440
Adjusted RFS (4 studies, n=576) 6.93 4.23–11.37 ,0.0001 3.61 (3) 0.306
NSCLC=non-small-cell lung cancer; HR=hazard ratio; CI=confidence interval; OS=overall survival; RFS=relapse-free survival.
doi:10.1371/journal.pone.0028844.t002
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analyses indicated that methods for BVI evaluation contributed
largely to heterogeneity. Thus, standardization of evaluating
vascular invasion and quality control is needed. In addition, an
important issue that needs to be taken into account is the type of
adjuvant therapy that each patient received because chemother-
apy and/or therapies that target the epidermal growth factor
receptor can change the outcome for NSCLC patients. However,
the majority of published studies lacked detailed information
regarding patient treatment. In this study, we used a methodology
assessment on the treatment of lung cancer reported by Steels et al
[3]. However, this approach does not fully protect from potential
bias because we could not take all the studies into account.
Therefore, our results need to be substantiated by further
prospective studies.
Publication and reporting bias also has to be considered. We did
not look for unpublished papers, reviews or abstracts because the
required data were usually available only in full publications.
Another potential source of bias is related to the method used to
extrapolate the HR. If the HR was not reported by author, it was
calculated from the data included in the article or extrapolated from
thesurvivalcurves,whichinvolvesmakingassumptions.Inaddition,
each study adjusted for different covariates and only the studies that
found significant results in univariate analysis performed multivar-
iate analysis; thus, pooling the results may have produced bias.
Nevertheless, no publication bias was detected using Egger’s test,
suggesting that the statistics obtained approximate theactual results.
In conclusion, the relative risk of recurrence and death for an
individual patient whose tumor showed BVI by neoplastic cells
was nearly 4 and 2 times higher, respectively, than that of a
patient whose tumor did not show BVI by neoplastic cells. We
have demonstrated the prognostic power of a single independent
pathologic marker for NSCLC. We suggest that NSCLC patients
with BVI receive adjunct systematic chemotherapy and that BVI
should be incorporated in the new edition of the TNM
classification. However, large, properly designed studies that
employ standard methodology to assess BVI are needed to
demonstrate whether BVI can provide prognostic information in
addition to the currently used TNM staging system. Moreover,
according to the recent report by Kato et al., the significance of a
combination of microvessel count and BVI could be more
important than that of either BVI or microvessel count alone
[74].
Supporting Information
Figure S1 The flow of the included studies.
(DOC)
Checklist S1 PRISMA checklist.
(DOC)
Table S1 Data source for the estimating of HR form included
studies evaluating blood vessel invasion and prognosis.
(DOC)
Table S2 Characteristics of literatures excluded in this system-
atic review.
(DOC)
Table S3 Main characteristics and results of eligible studies
evaluating blood vessel invasion and RFS or OS in patients with
NSCLC.
(DOC)
Author Contributions
Conceived and designed the experiments: JW JC BW. Performed the
experiments: JW JC BW XC. Analyzed the data: JW JC BW XC KL JB.
Contributed reagents/materials/analysis tools: JW JC BW XC. Wrote the
paper: JW JC BW.
Figure 3. Forest plot showing the combined relative hazard ratio for overall survival of stage I patients by multivariate analysis.
doi:10.1371/journal.pone.0028844.g003
Blood Vessel Invasion and NSCLC Prognosis
PLoS ONE | www.plosone.org 6 December 2011 | Volume 6 | Issue 12 | e28844References
1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) CA Cancer J Clin
61: 69–90.
2. Chansky K, Sculier JP, Crowley JJ, Giroux D, Van Meerbeeck J, et al. (2009)
The International Association for the Study of Lung Cancer Staging Project:
prognostic factors and pathologic TNM stage in surgically managed non-small
cell lung cancer. J Thorac Oncol 4: 792–801.
3. Steels E, Paesmans M, Berghmans T, Branle F, Lemaitre F, et al. (2001) Role of
p53 as a prognostic factor for survival in lung cancer: a systematic review of the
literature with a meta-analysis. Eur Respir J 18: 705–719.
4. Meert AP, Martin B, Delmotte P, Berghmans T, Lafitte JJ, et al. (2002) The role
of EGF-R expression on patient survival in lung cancer: a systematic review with
meta-analysis. Eur Respir J 20: 975–981.
5. Mascaux C, Martin B, Paesmans M, Berghmans T, Dusart M, et al. (2006) Has
Cox-2 a prognostic role in non-small-cell lung cancer? A systematic review of the
literature with meta-analysis of the survival results. Br J Cancer 95: 139–145.
6. Wang J, Wang B, Chen X, Bi J (2011) The prognostic value of RASSF1A
promoter hypermethylation in non-small cell lung carcinoma: a systematic
review and meta-analysis. Carcinogenesis 32: 411–416.
7. Greene FL, Sobin LH (2009) A worldwide approach to the TNM staging system:
collaborative efforts of the AJCC and UICC. J Surg Oncol 99: 269–272.
8. Macchiarini P, Fontanini G, Hardin MJ, Chuanchieh H, Bigini D, et al. (1993)
Blood vessel invasion by tumor cells predicts recurrence in completely resected
T1 N0 M0 non-small-cell lung cancer. J Thorac Cardiovasc Surg 106: 80–89.
9. Maeda R, Yoshida J, Ishii G, Hishida T, Nishimura M, et al. (2011) Poor
prognostic factors in patients with stage IB non-small cell lung cancer according
to the seventh edition TNM classification. Chest 139: 855–861.
10. Maeda R, Yoshida J, Hishida T, Aokage K, Nishimura M, et al. (2010) Late
recurrence of non-small cell lung cancer more than 5 years after complete
resection: incidence and clinical implications in patient follow-up. Chest 138:
145–150.
11. Maeda R, Yoshida J, Ishii G, Aokage K, Hishida T, et al. (2010) Long-term
outcome and late recurrence in patients with completely resected stage IA non-
small cell lung cancer. J Thorac Oncol 5: 1246–1250.
12. Turhan K, Samancilar O, Cagirici U, Goksel T, Nart D, et al. (2010) The effect
of blood vessel invasion on prognosis of operated stage I non-small cell lung
cancer patients. Thorac Cardiovasc Surg 58: 28–31.
13. Shoji F, Haro A, Yoshida T, Ito K, Morodomi Y, et al. (2010) Prognostic
significance of intratumoral blood vessel invasion in pathologic stage IA non-
small cell lung cancer. Ann Thorac Surg 89: 864–869.
14. Kashiwabara K, Saeki S, Sasaki J, Nomura M, Kohrogi H (2008) Combined
evaluation of postoperative serum levels of carcinoembryonic antigen less than
or equal to 2.5 ng/ml and absence of vascular invasion may predict no
recurrence of stage I adenocarcinoma lung cancer. J Thorac Oncol 3:
1416–1420.
15. Kawachi R, Tsukada H, Nakazato Y, Takei H, Furuyashiki G, et al. (2009)
Early recurrence after surgical resection in patients with pathological stage I
non-small cell lung cancer. Thorac Cardiovasc Surg 57: 472–475.
16. Okada M, Sakamoto T, Nishio W, Uchino K, Tsubota N (2003) Characteristics
and prognosis of patients after resection of nonsmall cell lung carcinoma
measuring 2 cm or less in greatest dimension. Cancer 98: 535–541.
17. Gabor S, Renner H, Popper H, Anegg U, Sankin O, et al. (2004) Invasion of
blood vessels as significant prognostic factor in radically resected T1-3N0M0
non-small-cell lung cancer. Eur J Cardiothorac Surg 25: 439–442.
18. Rigau V, Molina TJ, Chaffaud C, Huchon G, Audouin J, et al. (2002) Blood
vessel invasion in resected non small cell lung carcinomas is predictive of
metastatic occurrence. Lung Cancer 38: 169–176.
19. Ogawa J, Tsurumi T, Yamada S, Koide S, Shohtsu A (1994) Blood vessel
invasion and expression of sialyl Lewisx and proliferating cell nuclear antigen in
stage I non-small cell lung cancer. Relation to postoperative recurrence. Cancer
73: 1177–1183.
20. Shao W, Wang W, Xiong XG, Cao C, Yan TD, et al. (2011) Prognostic impact
of MMP-2 and MMP-9 expression in pathologic stage IA non-small cell lung
cancer. J Surg Oncol 104: 841–846.
21. Shimada Y, Ishii G, Hishida T, Yoshida J, Nishimura M, et al. (2010)
Extratumoral vascular invasion is a significant prognostic indicator and a
predicting factor of distant metastasis in non-small cell lung cancer. J Thorac
Oncol 5: 970–975.
22. Naito Y, Goto K, Nagai K, Ishii G, Nishimura M, et al. (2010) Vascular invasion
is a strong prognostic factor after complete resection of node-negative non-small
cell lung cancer. Chest 138: 1411–1417.
2 3 .Y a m a g u c h iY ,I s h i iG ,K o j i m aM ,Y o hK ,O t s u k aH ,e ta l .( 2 0 1 0 )
Histopathologic features of the tumor budding in adenocarcinoma of the lung:
tumor budding as an index to predict the potential aggressiveness. J Thorac
Oncol 5: 1361–1368.
24. Ryuge S, Sato Y, Wang GQ, Matsumoto T, Jiang SX, et al. (2011) Prognostic
significance of nestin expression in resected non-small cell lung cancer. Chest
139: 862–869.
25. Bodendorf MO, Haas V, Laberke HG, Blumenstock G, Wex P, et al. (2009)
Prognostic value and therapeutic consequences of vascular invasion in non-small
cell lung carcinoma. Lung Cancer 64: 71–78.
26. Kawachi R, Nakazato Y, Masui K, Takei H, Koshi-ishi Y, et al. Clinical
significance of pleural lavage cytology for non-small cell lung cancer: is surgical
resection valid for patients with positive pleural lavage cytology? Interact
Cardiovasc Thorac Surg 9: 265–268.
27. Mizuno T, Ishii G, Nagai K, Yoshida J, Nishimura M, et al. (2008) Identification
of a low risk subgroup of stage IB lung adenocarcinoma patients. Lung Cancer
62: 302–308.
28. Hashizume S, Nagayasu T, Hayashi T, Hidaka S, Tsuchiya T, et al. (2009)
Accuracy and prognostic impact of a vessel invasion grading system for stage IA
non-small cell lung cancer. Lung Cancer 65: 363–370.
29. Rao J, Sayeed RA, Tomaszek S, Fischer S, Keshavjee S, et al. (2007) Prognostic
factors in resected satellite-nodule T4 non-small cell lung cancer. Ann Thorac
Surg 84: 934–938.
30. Ayed AK, Adesina A (2006) Prognostic significance of cyclin D1 expression in
resected stage I, II non-small cell lung cancer in Arabs. Interact Cardiovasc
Thorac Surg 5: 47–51.
31. Takanami I (2005) Increased expression of integrin-linked kinase is associated
with shorter survival in non-small cell lung cancer. BMC Cancer 5: 1.
32. Barle ´si F, Doddoli C, Torre JP, Giudicelli R, Fuentes P, et al. (2005)
Comparative prognostic features of stage IIIAN2 and IIIB non-small-cell lung
cancer patients treated with surgery after induction therapy. Eur J Cardiothorac
Surg 28: 629–634.
33. Wu CT, Chang YL, Shih JY, Lee YC (2005) The significance of estrogen
receptor beta in 301 surgically treated non-small cell lung cancers. J Thorac
Cardiovasc Surg 130: 979–986.
34. Mineo TC, Ambrogi V, Baldi A, Rabitti C, Bollero P, et al. (2004) Prognostic
impact of VEGF, CD31, CD34, and CD105 expression and tumour vessel
invasion after radical surgery for IB-IIA non-small cell lung cancer. J Clin Pathol
57: 591–597.
35. Yamamoto S, Tomita Y, Hoshida Y, Iizuka N, Monden M, et al. (2004)
Expression level of valosin-containing protein (p97) is correlated with
progression and prognosis of non-small-cell lung carcinoma. Ann Surg Oncol
11: 697–704.
36. Okada M, Sakamoto T, Nishio W, Uchino K, Tsuboshima K, et al. (2003)
Pleural lavage cytology in non-small cell lung cancer: lessons from 1000
consecutive resections. J Thorac Cardiovasc Surg 126: 1911–1915.
37. Khan OA, Fitzgerald JJ, Field ML, Soomro I, Beggs FD, et al. (2004)
Histological determinants of survival in completely resected T1-2N1M0
nonsmall cell cancer of the lung. Ann Thorac Surg 77: 1173–1178.
38. Moriya Y, Niki T, Yamada T, Matsuno Y, Kondo H, et al. (2001) Increased
expression of laminin-5 and its prognostic significance in lung adenocarcinomas
of small size. An immunohistochemical analysis of 102 cases. Cancer 91:
1129–1141.
39. Tamura A, Hebisawa A, Hayashi K, Sagara Y, Fukushima K, et al. (2001)
Prognostic significance of thrombomodulin expression and vascular invasion in
stage I squamous cell carcinoma of the lung. Lung Cancer 34: 375–382.
40. Thomas P, Doddoli C, Thirion X, Ghez O, Payan-Defais MJ, et al. (2002) Stage
I non-small cell lung cancer: a pragmatic approach to prognosis after complete
resection. Ann Thorac Surg 73: 1065–1070.
41. Yokose T, Suzuki K, Nagai K, Nishiwaki Y, Sasaki S, et al. (2000) Favorable and
unfavorable morphological prognostic factors in peripheral adenocarcinoma of
the lung 3 cm or less in diameter. Lung Cancer 29: 179–188.
42. Suzuki K, Nagai K, Yoshida J, Nishimura M, Takahashi K, et al. (1999)
Conventional clinicopathologic prognostic factors in surgically resected nonsmall
cell lung carcinoma. A comparison of prognostic factors for each pathologic
TNM stage based on multivariate analyses. Cancer 86: 1976–1984.
43. Kessler R, Gasser B, Massard G, Roeslin N, Meyer P, et al. (1996) Blood vessel
invasion is a major prognostic factor in resected non-small cell lung cancer. Ann
Thorac Surg 62: 1489–1493.
44. Duarte IG, Bufkin BL, Pennington MF, Gal AA, Cohen C, et al. (1998)
Angiogenesis as a predictor of survival after surgical resection for stage I non-
small-cell lung cancer. J Thorac Cardiovasc Surg 115: 652–658.
45. Fujisawa T, Yamaguchi Y, Saitoh Y, Hiroshima K, Ohwada H (1995) Blood
and lymphatic vessel invasion as prognostic factors for patients with primary
resected nonsmall cell carcinoma of the lung with intrapulmonary metastases.
Cancer 76: 2464–2470.
46. Harpole DH, Jr., Herndon JE, 2nd, Young WG, Jr., Wolfe WG, Sabiston DC, Jr.
(1995) Stage I nonsmall cell lung cancer. A multivariate analysis of treatment
methods and patterns of recurrence. Cancer 76: 787–796.
47. Ichinose Y, Yano T, Asoh H, Yokoyama H, Yoshino I, et al. (1995) Prognostic
factors obtained by a pathologic examination in completely resected non-small-
cell lung cancer. An analysis in each pathologic stage. J Thorac Cardiovasc Surg
110: 601–605.
48. Matsuguma H, Nakahara R, Igarashi S, Ishikawa Y, Suzuki H, et al. (2008)
Pathologic stage I non-small cell lung cancer with high levels of preoperative
serum carcinoembryonic antigen: clinicopathologic characteristics and progno-
sis. J Thorac Cardiovasc Surg 135: 44–49.
49. Yoshida T, Tanaka S, Mogi A, Shitara Y, Kuwano H (2004) The clinical
significance of Cyclin B1 and Wee1 expression in non-small-cell lung cancer.
Ann Oncol 15: 252–256.
50. Cagini L, Monacelli M, Giustozzi G, Moggi L, Bellezza G, et al. (2000)
Biological prognostic factors for early stage completely resected non-small cell
lung cancer. J Surg Oncol 74: 53–60.
Blood Vessel Invasion and NSCLC Prognosis
PLoS ONE | www.plosone.org 7 December 2011 | Volume 6 | Issue 12 | e2884451. Fu XL, Zhu XZ, Shi DR, Xiu LZ, Wang LJ, et al. (1999) Study of prognostic
predictors for non-small cell lung cancer. Lung Cancer 23: 143–152.
52. Hirata T, Fukuse T, Naiki H, Hitomi S, Wada H (1998) Expression of CD44
variant exon 6 in stage I non-small cell lung carcinoma as a prognostic factor.
Cancer Res 58: 1108–1110.
53. Lucchi M, Fontanini G, Mussi A, Vignati S, Ribechini A, et al. (1997) Tumor
angiogenesisandbiologicmarkersinresectedstageINSCLC.EurJCardiothorac
Surg 12: 535–541.
54. Bre ´chot JM, Chevret S, Charpentier MC, Appere de Vecchi C, Capron F, et al.
(1996) Blood vessel and lymphatic vessel invasion in resected nonsmall cell lung
carcinoma. Correlation with TNM stage and disease free and overall survival.
Cancer 78: 2111–2118.
55. Roberts TE, Hasleton PS, Musgrove C, Swindell R, Lawson RA (1992) Vascular
invasion in non-small cell lung carcinoma. J Clin Pathol 45: 591–593.
56. Sakai Y, Ohbayashi C, Kanomata N, Kajimoto K, Sakuma T, et al. (2011)
Significance of microscopic invasion into hilar peribronchovascular soft tissue in
resection specimens of primary non-small cell lung cancer. Lung Cancer 73: 89–95.
57. Ruffini E, Asioli S, Filosso PL, Buffoni L, Bruna MC, et al. (2011) Significance of
the presence of microscopic vascular invasion after complete resection of Stage I-
II pT1-T2N0 non-small cell lung cancer and its relation with T-Size categories:
did the 2009 7th edition of the TNM staging system miss something? J Thorac
Oncol 6: 319–326.
58. Shimizu K, Yoshida J, Nagai K, Nishimura M, Ishii G, et al. (2005) Visceral
pleural invasion is an invasive and aggressive indicator of non-small cell lung
cancer. J Thorac Cardiovasc Surg 130: 160–165.
59. Gao Y, Zhang C, Li N, Zhou F, Shi S, He J (2008) Vascular invasion as an
independent prognostic indicator in radically resected non-small cell lung
cancer. Chin J Cancer Res 20: 33–38.
60. Maeda R, Yoshida J, Ishii G, Hishida T, Nishimura M, et al. (2010) Prognostic
impact of intratumoral vascular invasion in non-small cell lung cancer
patients.Thorax 65: 1092–1098.
61. Parmar MK, Torri V, Stewart L (1998) Extracting summary statistics to perform
meta-analyses of the published literature for survival endpoints. Stat Med 17:
2815–2834.
62. Whitehead A, Whitehead J (1991) A general parametric approach to the meta-
analysis of randomized clinical trials. Stat Med 10: 1665–1677.
63. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis
detected by a simple, graphical test. BMJ 315: 629–634.
64. Takanami I (2005) The prognostic value of overexpression of Skp2 mRNA in
non-small cell lung cancer. Oncol Rep 13: 727–731.
65. Harpole DH, Jr., Herndon JE, 2nd, Wolfe WG, Iglehart JD, Marks JR (1995) A
prognostic model of recurrence and death in stage I non-small cell lung cancer
utilizing presentation, histopathology, and oncoprotein expression. Cancer Res
55: 51–56.
66. Fontanini G, Macchiarini P, Pepe S, Ruggiero A, Hardin M, et al. (1992) The
expression of proliferating cell nuclear antigen in paraffin sections of peripheral,
node-negative non-small cell lung cancer. Cancer 70: 1520–1527.
67. Macchiarini P, Fontanini G, Hardin JM, Pingitore R, Angeletti CA (1992) Most
peripheral, node-negative, non-small-cell lung cancers have low proliferative
rates and no intratumoral and peritumoral blood and lymphatic vessel invasion.
Rationale for treatment with wedge resection alone. J Thorac Cardiovasc Surg
104: 892–899.
68. Macchiarini P, Dulmet E, De Montpreville V, Chapelier A, Cerrina J, et al.
(1995) Prognostic significance of peritumoural blood and lymphatic vessel
invasion by tumour cells in T4 non-small cell lung cancer following induction
therapy. Surg Oncol 4: 91–99.
69. Anami Y, Iijima T, Suzuki K, Yokota J, Minami Y, et al. (2009)
Bronchioloalveolar carcinoma (lepidic growth) component is a more useful
prognostic factor than lymph node metastasis. J Thorac Oncol 4: 951–958.
70. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell
144: 646–674.
71. Roxburgh CS, McMillan DC, Anderson JH, McKee RF, Horgan PG, et al.
(2010) Elastica staining for venous invasion results in superior prediction of
cancer-specific survival in colorectal cancer. Ann Surg 252: 989–997.
72. Mohammed RA, Ellis IO, Mahmmod AM, Hawkes EC, Green AR, et al. (2011)
Lymphatic and blood vessels in basal and triple-negative breast cancers:
characteristics and prognostic significance. Mod Pathol 24: 774–785.
73. Kim JH, Park SS, Park SH, Kim SJ, Mok YJ, et al. (2010) Clinical significance of
immunohistochemically-identified lymphatic and/or blood vessel tumor inva-
sion in gastric cancer. J Surg Res 162: 177–183.
74. Kato T, Kameoka S, Kimura T, Nishikawa T, Kobayashi M (2003) The
combination of angiogenesis and blood vessel invasion as a prognostic indicator
in primary breast cancer. Br J Cancer 88: 1900–1908.
Blood Vessel Invasion and NSCLC Prognosis
PLoS ONE | www.plosone.org 8 December 2011 | Volume 6 | Issue 12 | e28844